Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice

Circulation

Volumn 97, Issue 3, 1998, Pages 242-244

  Elhage, R ^a   Maret, A ^a   Pieraggi, M T ^b   Thiers, J C ^b   Arnal, J F ^a   Bayard, F ^a,b  

^a INSERM   (France)

^b CHU RANGUEIL   (France)

Author keywords

Apolipoproteins; Atherosclerosis; Interleukins; Tumor necrosis factor

Indexed keywords

APOLIPOPROTEIN E; ESTRADIOL; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR BINDING PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; FATTY ACID TRANSPORT; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0032570269     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.3.242     Document Type: Article

References (23)

1. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
3. Brett J, Gerlach H, Nawroth P. Steinberg S, Godman G, Stem D. Tumor necrosis fector/cachectin increases permeability of endothelial cell mono-layers by a mechanism involving regulatory G proteins. J Exp Med. 1989;169:1977-1991.
4. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MAJ. Interleukin-1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest. 1985;76:2003-2011.
5. Wang X, Feuerstein GZ, Gu L, Lysko PG, Yue TL. IL-1β induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis. 1995;115:89-98.
6. Loppnow H, Libby P. Functional significance of human vascular smooth muscle cell-derived interleukin 1 in paracrine and autocrine regulation pathways. Exp Cell Res. 1992;198:283-290.
7. Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage-colony stimulating actor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol. 1992;140:301-316.
8. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1- and tumor necrosis actor-mediated stimulation of macrophage colony-stimulating actor production. J Biol Chem. 1996;271:28890-28897.
9. Rosenfeld ME, Ylä-Hertuala S, Lipton BA, Ord VA, Witztum JL, Steinberg D. Macrophage-colony stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am J Pathol. 1992;140:291-300.
10. Plump AS, Smith JD, Hayek T. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
11. Zhang SH, Reddick RL, Burkey B, Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest. 1994;94:937-945.
12. Arend WP, Joslin FG, Thompson RC, Hannum CH. An IL-1 inhibitor from human monocytes. J Immunol. 1989;143:1851-1858.
13. Arend WP. Interleukin 1 receptor antagonist: a new member of the interleukin 1 family. J Clin Invest. 1991;88:1445-1451.
14. Kohno T, Brewer MT, Baker SL, Schwartz PE, King MW, Hale KK, Squires CH, Thompson RC, Vannice JL. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A. 1990;87:8331-8335.
15. Hale KK, Smith CG, Baker SL, Vanderslice RW, Squires CH, Gleason TM, Tucker KK, Kohno T, Russell DA. Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors. Cytokine. 1995;7:26-38.
16. Russell DA, Tucker KK, Chinookoswong N, Thompson RC, Kohno T. Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: improved survival and organ function. J Infect Dis. 1995;171:1528-1538.
17. Bourassa PAK, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice, Proc Natl Acad Sci USA. 1996;93:10022-10027.
18. Elhage R, Arnal JF, Pierragi MT, Duverger N, Fievet C, Faye JC, Bayard F. 17β-Estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. In press.
19. Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest. 1994;94:2397-2406.
20. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J, Towne E, Tracey D, Wardwell S, Wei F-Y, Wong W, Kamen R, Seshadri T. Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxin shock. Cell. 1995;80:401-411.
21. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science. 1994;264:667-668.
22. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev. 1996;17:369-384.
23. Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem. 1996;271:26174-26178.